ArticleJournal of fluorescence2026
Functional Versatility of Sulfonamide-pyrazole Derivative: From Antibacterial Activity to Metal ion Sensing Aptitude.
Article in Journal of fluorescence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In this study, a novel sulfonamide-Schiff base derivative, ethyl (Z)-2-(5-chloro-3-methyl-4-((2-tosylhydrazono) methyl)-1H-pyrazol-1-yl)acetate 6, was synthesized to address sulfonamide resistance and explore its therapeutic potential. The molecular structure was confirmed through comprehensive spectroscopic analyses including FT-IR, 1H & 13C NMR and mass spectrometry, providing strong evidence for the proposed architecture. Antibacterial evaluation revealed that compound 6 pyrazole exhibited notable antibacterial activity against Staphylococcus aureus (inhibition zones up to 1.2 mm), with comparatively moderate activity against Escherichia coli (0.6–0.7 mm). Molecular docking studies demonstrated pronounced binding affinities toward DNA gyrase and β-lactamase, corroborating its observed antibacterial efficacy and suggesting promising therapeutic relevance. Notably, the compound also displayed sensitive and selective chemosensing for Fe3+ (0.27 µM) and Fe2+ (0.12 µM), highlighting its multifunctional profile as both a potent antibacterial agent and a metal ion sensor. These findings indicate that compound 6 is a multifunctional bioactive scaffold and represents a promising lead for further investigation in antimicrobial and chemosensing applications.
Indexed as
Identifiers
41936704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.